chronic%20lymphocytic%20leukemia
CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia (CLL) is a malignant, chronic lymphoproliferative disorder characterized by proliferation and accumulation of monoclonal B-cells in the bone marrow, peripheral blood, lymph nodes, liver and spleen.

It is the most common form of adult leukemia in the Western world but rare in Asians.

Exact etiology is unknown but usually associated with genetic aberrations and lesions.

 

Chronic Lymphocytic Leukemia Drug Information

Drug Information

Indication: Agammaglobulinemia/hypogammaglobulinemia. Combined therapy w/ antibiotics in severe bacterial or viral infecti...

Indication: Adult patients w/ relapsed or refractory mantle cell lymphoma (MCL), previously untreated chronic lymphocytic ...

Indication: Monotherapy in patients w/ chronic lymphocytic leukaemia; indolent B-cell non-Hodgkin's lymphomas that has pro...

Indication: Adjuvant of maintenance therapy & short-term administration in psoriatic arthritis, ankylosing spondylitis...

Indication: Replacement therapy in primary immunodeficiency syndromes eg, congenital agammaglobulinaemia & hypogammagl...

Indication: Primary humoral immunodeficiency. Idiopathic thrombocytopenic purpura. Chronic inflammatory demyelinating poly...

Indication: In combination w/ chemotherapy, followed by maintenance therapy in patients achieving a response for previousl...

Indication: Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, Waldenstrom's macro...

Indication: Relapsed or chemoresistant low-grade or follicular, CD20 +ve, B-cell non-Hodgkin's lymphoma (NHL); previously ...

Indication: Relapsed or chemoresistant low-grade or follicular, CD20 +ve, B-cell non-Hodgkin's lymphoma (NHL); previously ...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 09 Oct 2020

Individualized starting dose (ISD) of maintenance niraparib improves progression-free survival (PFS) vs placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), results of the NORA trial have shown.

Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.